In LNCaP human prostate cancer cells, the PPARα (NR1C1) agonist fenofibrate was able to mitigate against the androgen receptor agonist‐evoked increase in TMPRSS2 expression (Zhao et al., 2013). Here, TMPRSS2 is linked to prostate carcinoma.